• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Adventrx establishes regulatory advisory board

Adventrx establishes regulatory advisory board

April 9, 2012
CenterWatch Staff

San Diego-based Adventrx Pharmaceuticals has established a regulatory advisory board, which will provide drug development and regulatory affairs guidance on the company’s interactions with the FDA.

Frank J. Sasinowski, M.S., M.P.H., JD, will be advising the regulatory advisory board as a director at Hyman, Phelps & McNamara, P.C., a law firm with one of the most extensive food and drug practices in the U.S. Sasinowski assists sponsors in developing new medicines and has helped secure FDA approval for hundreds of new drugs including more than 45 novel therapies for serious and rare diseases. Sasinowski had a key role in implementing both the 1983 Orphan Drug law and the 1984 Hatch-Waxman law, and has received the FDA Award of Merit twice. In 1987, Sasinowski left the FDA and joined Hyman, Phelps & McNamara. He is also a current at-large member and a former chair of the board of directors of the National Organization for Rare Disorders (NORD).

Cindy Dinella, R.Ph., Pharm. D., is founder, president and managing partner at Advyzom, a boutique consulting company specializing in highly strategic regulatory and development advice and services for the pharmaceutical and healthcare industry. Dinella has over 20 years of experience and formerly served as the vice president of Drug Regulatory Affairs, the Nutley Site head for global development and member of the CEO's North American Operating Committee at Hoffman La Roche. She has filed over 100 IND filings across various therapeutic, filed and received approval for over 35 New Molecular Entities (NMES) and major efficacy supplements, and developed and managed 13 Risk Evaluation Mitigation Strategies (REMS).

Bonnie Hepburn, M.D., is a rheumatologist with more than 20 years of experience in drug development and was formerly chair of the FDA's Arthritis Advisory Committee. She currently serves as a clinical professor in the department of medicine, division of rheumatology/allergy/immunology at the University of California, San Diego and as a consultant to private and public pharmaceutical and biopharmaceutical companies. Hepburn has been directly involved in planning clinical and regulatory strategy for multiple products including new molecular entities, both xenobiotics and biologic agents, across different platforms and multiple therapeutic areas. Previously, she has served in senior drug and clinical development roles at Novartis, La Jolla Pharmaceutical and Santarus.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing